KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kalaris Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.91−0.09 (-4.50%)
Close on Oct 19, 2026
- Market cap
- $45.45M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.72 (−58.75%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $45.45M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.79
- Dividend yield
- –
- Free cash flow yield
- -84.86%
Fundamentals
- Net income
- -$44.26M
- EPS, diluted
- -$2.85
- Free cash flow
- -$38.57M
- Book value per share
- $2.42
- Diluted shares
- 24M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$47.76M
Net income
-$44.26M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months